# IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren

Source: https://onco.cc/trials/nct06014528/  
OnCo record `nct06014528` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of IN10018, Pegylated liposomal doxorubicin in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.

## Summary

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT06014528 by InxMed (Shanghai) Co., Ltd., with 168 participants planned, started 2022-09-06 and due to reach its primary completion in 2026-12-24. Interventions recorded: IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin. Conditions listed: Ovarian Cancer Recurrent. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06014528
- Phase: 2
- Setting: A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
- Sponsor: InxMed (Shanghai) Co., Ltd.
- Enrolled: 168

## Sources

- ClinicalTrials.gov NCT06014528: https://clinicaltrials.gov/study/NCT06014528

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [IN10018](https://onco.cc/drugs/in10018/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/)
- companies: [InxMed (Shanghai)](https://onco.cc/companies/inxmed-shanghai/)

---
JSON: https://onco.cc/api/v1/entities/nct06014528.json